FindTrial
Sign In

Comparison of platelet aggregation of ticagrelor 180 mg, clopidogrel 600 mg loading dose and prasugrel 60 mg loading dose and correlation of response of platelet aggregation to CYP2C19*2, *3, and *17 single nucleotide polymorphisms in Thai patients who planned undergoing coronary angiography

Comparison of platelet aggregation of ticagrelor 180 mg, clopidogrel 600 mg loading dose and prasugrel 60 mg loading dose and correlation of response of platelet aggregation to CYP2C19*2, *3, and *17 single nucleotide polymorphisms in Thai patients w

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170303002
Enrollment
Unknown
Registered
2017-03-03
Start date
2016-02-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thai patients who planned undergoing coronary angiography platelet aggregation&#44

Interventions

Ticagrelor is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y12 receptor. The drug was approved by the US Food and Drug Administration on July 20&#44
2011. Ticagrelor is used for the prevention of thrombotic events in people with acute coronary syndrome or myocardial infarction with ST elevation.,Clopidogrel is a medication that is used to reduce t
and in the US in July 2009&#44
for the reduction of thrombotic cardiovascular events.
Experimental Drug,Experimental Drug,Experimental Drug
Ticagrelor (Brilinta®90 mg Tablets),Clopidogrel (Plavix® 75 mg Tablets),Prasugrel (Effient® 10 mg Tablets)

Sponsors

Faculty of Medicine, Chulalongkorn University
Lead Sponsor
Astra Zeneca
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Thai patients who suspected to coronary heart disease and planned undergoing coronary angiography at King Chulalongkorn Memorial Hospital 2. Thai patients who are competent to give informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breastfeeding 2. History of hypersensitivity to clopidogrel ticagrelor หรือ prasugrel 3. The patients who had shock, liver failure, severe infection, renal failure, or retain in emergency unit 4. The patients who had bleeding disorder, history of gastrointestinal bleeding, thrombocytopenia 5. Receiving treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) except low dose aspirin (equal or less than 81 mg) 6. Serum creatinine more than 2.5 mg/dl 7. Participation in any other clinical trials within 30 days

Design outcomes

Primary

MeasureTime frame
The platelet aggregation 0 (baseline) and 6 hours post dose Platelet function testing: Light transmission aggregometry—

Secondary

MeasureTime frame
The correlation of response of platelet aggregation to single nucleotide polymorphisms no Determination of single nucleotide polymorphisms by Real time PCR—

Countries

Thailand

Contacts

Public ContactSuphot Srimahachota

Chulalongkorn University

s_srimahachota@yahoo.co.th081-9183842

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026